Trial Profile
A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms FIL BVHD01
- 21 Jul 2020 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 16 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.